Substance / Medication

Dihydrotachysterol

Overview

Active Ingredient
dihydrotachysterol
RxNorm CUI
3429

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

17 trials linked to this intervention

17
Total Trials
2
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The prevalence and anatomy of parathyroid glands: a meta-analysis with implications for parathyroid surgery.
Taterra Dominik, Wong Linda M, Vikse Jens et al. · Langenbecks Arch Surg · 2019
PMID: 30762091Meta-AnalysisFull text (PMC)
Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis.
Liu Yang, Liu Ling-Yun, Jia Ye et al. · Drug Des Devel Ther · 2019
PMID: 30992658Meta-AnalysisFull text (PMC)
Dihydrotachysterol therapy for hypoparathyroidism: consequences of inadequate monitoring. Five cases and a review.
Quack I, Zwernemann C, Weiner S M et al. · Exp Clin Endocrinol Diabetes · 2005
PMID: 16025398Case Report
Synthesis of 28,28,28-trideutero-25-hydroxydihydrotachysterol.
Sigüeiro Rita, Loureiro Julian, González-Berdullas Patricia et al. · J Steroid Biochem Mol Biol · 2019
PMID: 30244048Other
Dihydrotachysterol intoxication treated with pamidronate: a case report.
Jensterle Mojca, Pfeifer Marija, Sever Matjaz et al. · Cases J · 2010
PMID: 20507648OtherFull text (PMC)
[Severe Vitamin D(dihydrotachysterol)-intoxication with temporary anemia and hypercalcemia responsive to bisphosphonates]
Blind E, Fassnacht M, Körber C et al. · Dtsch Med Wochenschr · 2001
PMID: 12751020Other
Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2).
Fan S L, Schroeder N J, Calverley M J et al. · Nephrol Dial Transplant · 2000
PMID: 11096138Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dihydrotachysterol (substance)
SNOMED CT
126235007
UMLS CUI
C0012319
RxNorm CUI
3429

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
17
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.